As presented at Table 1 subgroup 2, FTC with non-oncocytic diagnostics and without capsular invasion exhibited a 7.7-fold upregulation of CHEK1 and a 2-fold downregulation of TPO. Similar results, with slightly stronger fold changes for both markers, were observed for non-oncocytic FTC with vascular invasion (Table 1, subgroup 3). The gene discussed is CHEK1; the disease is thyroid cancer, nonmedullary, 2.